Table 2.

Summary of Clinical Pharmacogenetics Implementation Consortium guidelines.

Drug(s)	Gene(s)	CPIC recommendations	Ref.
Azathioprine, 6-mercaptopurine and thioguanine	TPMT	Dosing recommendations based on TPMT genotype	[9]
Clopidogrel	CYP2C19	Recommendations for alternative treatment based on CYP2C19 genotype in post-percutaneous coronary intervention patients being considered for clopidogrel	[10]
Warfarin	VKORC1/CYP2C9	Recommendations for use of pharmacogenetic algorithms that incorporate VKORC1 and CYP2C9 genotype with clinical factors for warfarin dose prediction	[11]
Codeine	CYP2D6	Recommendation to avoid codeine in individuals with ultrarapid or poor metabolizer phenotype predicted based on CYP2D6 genotype	[12]
Abacavir	HLA-B	Recommendation to avoid abacavir in individuals positive for HLA-B*57:01 genotype	[13]
Simvastatin	SLCO1B1	Guidance for simvastatin use or dosing based on SLCO1B1 genotype	[14]
Allopurinol	HLA-B	Recommendation to avoid allopurinol in individuals positive for HLA-B*58:01 genotype	[15]
Tricyclic antidepressants	CYP2D6/CYP2C19	Dosing recommendations for tricyclic antidepressants based on CYP2D6 and CYP2C19 genotype	[16]

See [102] for update on published and in progress CPIC guidelines.

CPIC: Clinical Pharmacogenetics Implementation Consortium.